1. Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation
- Author
-
Kelen C. R. Malmegrim, Gabriela Trentin Scortegagna, Gislane Lelis Vilela de Oliveira, Patricia Vianna Bonini Palma, Carlos Tostes Guerreiro, Doralina Guimarães Brum, Amilton Antunes Barreira, Evandra Strazza Rodrigues, Júlio César Voltarelli, Maria Carolina Oliveira, Dimas Tadeu Covas, Júlia Teixeira Cottas de Azevedo, Belinda Pinto Simões, Lucas C. M. Arruda, Vanessa Daccach Marques, University of S�o Paulo, and Universidade Estadual Paulista (Unesp)
- Subjects
0301 basic medicine ,Male ,Disease status ,Time Factors ,medicine.medical_treatment ,T-Lymphocytes ,Programmed Cell Death 1 Receptor ,Hematopoietic stem cell transplantation ,CD8-Positive T-Lymphocytes ,T-Lymphocytes, Regulatory ,Immune tolerance ,0302 clinical medicine ,PD-1 ,Outcome Assessment, Health Care ,Immunology and Allergy ,B-Lymphocytes ,biology ,Hematopoietic Stem Cell Transplantation ,Immunosuppression ,Middle Aged ,Disease Progression ,Female ,Signal Transduction ,Adult ,Regulatory T-cells ,Immunology ,Antigens, CD19 ,Thymus Gland ,Transplantation, Autologous ,CD19 ,Multiple sclerosis ,03 medical and health sciences ,Young Adult ,Immune system ,Multiple Sclerosis, Relapsing-Remitting ,medicine ,Humans ,Lymphocyte Count ,Retrospective Studies ,business.industry ,Immunoregulation ,Immune reconstitution ,medicine.disease ,TRANSPLANTE AUTÓLOGO ,030104 developmental biology ,biology.protein ,business ,CD8 ,030215 immunology - Abstract
Made available in DSpace on 2018-12-11T17:23:08Z (GMT). No. of bitstreams: 0 Previous issue date: 2016-08-01 High dose immunosuppression followed by autologous hematopoietic stem cell transplantation (AHSCT) induces prolonged clinical remission in multiple sclerosis (MS) patients. However, how patient immune profiles are associated with clinical outcomes has not yet been completely elucidated. In this study, 37 MS patients were assessed for neurological outcomes, thymic function and long-term immune reconstitution after AHSCT. Patients were followed for a mean (SD) of 68.5 (13.9) months post-transplantation and were retrospectively clustered into progression- and non-progression groups, based on Expanded Disease Status Scale (EDSS) outcomes at last visit. After AHSCT, both patient groups presented increased regulatory T-cell subset counts, early expansion of central- and effector-memory CD8+ T-cells and late thymic reactivation. However, the non-progression group presented early expansion of PD-1+CD8+ T-cells and of PD-1-expressing CD19+ B-cells. Here, we suggest that along with increased numbers of regulatory T-cell subsets, PD-1 inhibitory signaling is one possible immunoregulatory mechanism by which AHSCT restores immune tolerance in MS patients. Center for Cell-based Therapy Regional Blood Center of Ribeir�o Preto Ribeir�o Preto Medical School University of S�o Paulo Department of Biochemistry and Immunology Ribeir�o Preto Medical School University of S�o Paulo Department of Neuroscience and Behavioral Science Ribeir�o Preto Medical School University of S�o Paulo Department of Internal Medicine Ribeir�o Preto Medical School University of S�o Paulo Universidade Estadual Paulista UNESP Department of Clinical Toxicological and Bromatological Analysis School of Pharmaceutical Sciences of Ribeir�o Preto University of S�o Paulo Universidade Estadual Paulista UNESP
- Published
- 2016